Cara Mathews, MD, Talks Dostarlimab for Advance Recurrent Endometrial Cancers
Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
CancerNetwork® spoke with Cara Mathews, MD, gynecologic oncology specialist at the Women and Infants Hospital of Rhode Island, about cohort results from the GARNET (NCT02715284) and ZopteC (NCT01767155) trials that were presented at The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer examining dostarlimab (Jemperli) compared with doxorubicin in patients with advance recurrent endometrial cancers.
Transcript:
The project that we presented at this meeting is looking at patients who are mismatch repair deficient. Typically, [they have tumors that are] microsatellite unstable and are treated with single-agent dostarlimab, PD-L1 inhibition, compared with patients from the zoptEC trial [NCT01767155], who were treated and matched with a standard doxorubicin arm. We had patient-level data and were able to compare in 2 clinical trial settings where we had very good data, rather than the clinical real-world setting, [to see] what the outcomes were. This is a novel trial method and it’s important because for dostarlimab, the outcomes have been so promising that it would be hard to do a head-to-head comparison for this treatment vs standard chemotherapy. Some would even argue that it might be unethical at this point, so we can use these data from these 2 populations and compare PD-L1 inhibitor vs standard chemotherapy. The results were exciting, and it showed that, not surprisingly, dostarlimab performed very well. Progression-free survival between the 2 arms showed a clear benefit towards dostarlimab, 12 months vs 5 months. In overall survival, the doxorubicin arm was about 11 months and it wasn’t reached in the dostarlimab arm. Survival outcomes were clearly beneficial for the PD-L1 inhibitor in this population.
Reference
Mathews C, Lorusso D, Coleman RL, et al. The comparative clinical effectiveness of dostarlimab versus doxorubicin in the treatment of advanced/recurrent endometrial cancer. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.
Dostarlimab With Chemo Changes Practice for dMMR Endometrial Cancer
August 20th 2024“The dMMR population, which are patients who have deficiency in their mismatch repair proteins, had the most pronounced impact in PFS, and we’re seeing that trend for prolonged periods of time; we may be curing many of these patients,” said Ritu Salani, MD.
